DT MedTech Announces the First US Implantation of the Hintermann Series H3™
September 24, 2019 (Baltimore, MD) – DT MedTech, LLC (DTM) announced today that the first Hintermann Series H3™ Total Ankle Replacement System (H3) has been successfully implanted in a patient in the United States. The surgery was performed, implanting the H3, three-component, non-constrained total ankle replacement system, at Lakewood Ranch Medical Center in Sarasota, Florida by Dr. James Cottom of Florida Orthopedic Foot and Ankle Center.
The Hintermann Series H3™ Total Ankle Replacement System is indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis, or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis, etc.).
Dr. Beat Hintermann, world-renowned foot and ankle surgeon, developed both the Hintermann Series H3™ and the Hintermann Series H2® Total Ankle Replacement Systems. Dr. Hintermann states, “Since the launch outside of the US (OUS) of the H3, it has been a goal of mine to also have the H3 available in the US. We reached a huge milestone in June of this year when we received PMA approval, one of only five PMA approvals to be given below the knee. This first surgery means that even more patients will now have access to this device with the positive clinical outcomes it has shown over the last 18 years OUS.”
Dr. Cottom observes, “It is remarkable that with one system, I can evaluate the needs of my patients to determine if a non-constrained or semi-constrained TAR works best with their anatomy. Having successfully implanted many Hintermann H2 semi-constrained ankles over the past year, to now have the option to also offer the non-constrained H3 ankle is truly a win-win for my patients. This first patient is doing exceptionally well at just about 4 weeks out from surgery and is already weight-bearing!!!!!”